Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga · 2d ago

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Perrigo Company PLC (NYSE:PRGO)

  • Dividend Yield: 7.09%
  • Canaccord Genuity analyst Susan Anderson maintained a Buy rating and cut the price target from $20 to $17 on Feb. 27, 2026. This analyst has an accuracy rate of 59%.
  • JP Morgan analyst Chris Schott maintained a Neutral rating and slashed the price target from $20 to $18 on Dec. 15, 2025. This analyst has an accuracy rate of 70%.
  • Recent News: Perrigo said it will release third quarter financial results on Nov. 4.
  • Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.

Pfizer Inc (NYSE:PFE)

  • Dividend Yield: 5.65%
  • JP Morgan analyst Chris Schott maintained a Neutral rating and raised the price target from $28 to $30 on Oct. 9, 2026. This analyst has an accuracy rate of 70%.
  • Cantor Fitzgerald analyst Carter Gould maintained a Neutral rating and increased the price target from $27 to $28 on Oct. 8, 2026. This analyst has an accuracy rate of 69%.
  • Recent News: On Oct. 7, the U.S. Food and Drug Administration approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab.
  • Benzinga Pro’s real-time newsfeed alerted to latest PFE news

CVS Health Corp (NYSE:CVS)

  • Dividend Yield: 2.82%
  • Leerink Partners analyst Michael Cherny maintained an Outperform rating and cut the price target from $119 to $112 on Oct. 12, 2026. This analyst has an accuracy rate of 67%.
  • UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $126 to $118 on Sept. 3, 2026. This analyst has an accuracy rate of 72%.
  • Recent News: On Oct. 15, CVS Health announced a new collaboration with The Midlife Collective to redefine a woman’s midlife health journey.
  • Benzinga Pro’s real-time newsfeed alerted to latest CVS news

Photo via Shutterstock